Abstract
21Feb 2017 SERUM GALECTIN-4 (GAL-4) IN PATIENTS WITH GASTRIC ADENOCARCINOMA: ACTIVE PLAYER IN THE FIELD. Ahmed Hamouda Arnaout and Lamya Mahmoud Ibrahim. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt. Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt.
Highlights
Galectin-4 is one of a β-galactosides binding proteinsReceived: 23 December 2016 Final Accepted: 27 January 2017 Published: February 2017 family that recognize a variety of glycan–containing proteins at the cell surface and are overexpressed in various tumors, including gastric cancer
Galectin-4 overexpression as well as changes in their subcellular distribution has been associated with gastric cancer
Serum levels of GAL-4 were significantly higher in patients with malignant gastric adenocarcinoma which may confirm a possible role of this marker in the pathogenesis of the disease, the highest sensitivity and best accuracy obtained from serum GAL-4 was by using a cut off values equal to or above
Summary
Received: 23 December 2016 Final Accepted: 27 January 2017 Published: February 2017 family that recognize a variety of glycan–containing proteins at the cell surface and are overexpressed in various tumors, including gastric cancer. Galectin-4 overexpression as well as changes in their subcellular distribution has been associated with gastric cancer. It may provide diagnostic molecular markers for gastric cancer as well as clues for developing therapeutic targets on individual basis. Aim of the study: To detect the levels of GAL-4 in the sera of healthy people and patients with gastric cancer and to investigate the validity of using GAL-4 as a specific diagnostic marker of gastric cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
